Lactobacillus rhamnosus GG is a well-characterized bacterium displaying great probiotic potential in a diversity of therapeutic areas. Creative Biolabs, a world-leading services provider in drug discovery, is dedicated to providing a full range of probiotic products and fast services for our worldwide customers.
Lactobacillus rhamnosus GG (L. rhamnosus GG, LGG), a strain of Lactobacillus rhamnosus (L. rhamnosus) species, is one of the most widely researched probiotic bacteria isolated from the intestinal tract of healthy individuals in 1983. It is a member of the genus of Lactobacillus and the family of Lactobacillaceae. Bacteriologically, LGG is a Gram-positive bacterium with rod shape and good adhesion to intestinal epithelial cells. When cultured, LGG usually forms creamy white colonies with a distinct buttery smell.
LGG is a well-documented probiotic strain with good resistance to acid and bile and the highest binding capacities among the Lactobacillus. A variety of commercial products based on LGG has been explored and developed, including food, dietary supplements, and therapeutic drugs, many of which are extensively investigated in numerous clinical trials for the effective treatment of human diseases.
Fig.1 Phenotypic characteristics of Lactobacillus rhamnosus GG. (Segers, 2014; Gorbach, 2017)
As one of the most characterized and utilized probiotics, LGG has been shown great benefits for the treatment of a variety of human diseases through several mechanisms.
The excellent adhesion properties to the intestinal mucosa and survival in a broad pH range and bile salts make LGG easier to colonize the intestine to function beneficial effects. Worldwide trials indicate that intestinal LGG exhibits effective prevention and treatment of diarrhea both in children and adults, including rotavirus-caused acute diarrhea and antibiotic-associated diarrhea. And LGG supplement has been demonstrated to prevent clostridium difficile infections.
The immune regulation effects of LGG have been extensively researched through the enhancement of the cellular immune response, anti-inflammatory response, and gut defense. All these immune-regulatory properties endow LGG great potential for the applications of pathogen prevention, allergic diseases treatment, and vaccination as a probiotic adjuvant.
Animal studies have revealed that LGG could prevent tumorigenesis by inducing tumor cell apoptosis, inhibiting the expression of angiogenesis and inflammation in colon cancer rates.
LGG has been widely evaluated as a promising probiotic bacterium in many other activities and treatments, such as intestinal microbiome alteration, anti-obesity, insulin sensitivity increase, depression and anxiety alleviation, inflammatory bowel disease, and dental health care.
Creative Biolabs has invested numerous energy and efforts in the development of Next-Generation probiotics for the various diseases therapy. We now provide a comprehensive range of products and services for the development of L. rhamnosus GG-based live biotherapeutic.
For any questions, please directly contact us for more details.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.